Editor's Note From December 14 to 23, 2020, after administration of 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine, the Centers for Disease Control and Prevention (CDC) identified 21 case reports of anaphylaxis. Of those, 4 (19%) were hospitalized (including 3 in intensive care), and 17 (81%) were treated in…

Read More

Editor's Note A study, led by researchers from Rockefeller University in New York City, finds that volunteers vaccinated with either the Moderna or the Pfizer/BioNTech vaccine will be protected against new variants of the COVID-19 virus. The researchers tested plasma taken from 20 volunteers who had received both doses of…

Read More

Editor's Note This study led by researchers from the Virginia Commonwealth University, Richmond, finds that COVID-19 vaccine-related messaging should address concerns about the vaccine and its development and reinforce its benefits to increase the willingness of US adults to get the COVID-19 vaccine and to get the vaccine under an…

Read More

Editor's Note Results from Johnson & Johnson’s early-stage trials for its COVID-19 vaccine showed neutralizing antibodies in all participants who received the vaccine when they were tested at 57 days. The J&J Ad26.COV2.S vaccine is different than the Pfizer-BioNTech and Moderna vaccines in that it is anenovirus-based rather than mRNA-based.…

Read More

Resiliency, a term that has cropped up repeatedly during the COVID-19 pandemic, is often considered a key defense against burnout. But it is also important in the context of the healthcare supply chain, says Ed Hisscock, senior vice president of supply chain management at Trinity Health, a 22-state healthcare system…

Read More

The rollout of COVID-19 vaccines starting in December 2020 was the one bright spot in an otherwise tragic year with a rapidly rising death toll currently over 385,000. Distribution of the 20 million doses promised by year end was thwarted by problems such as lack of coordination and lack of…

Read More

Editor's Note This study led by researchers from the Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, finds that response to COVID-19 by the immune system can last for at least 8 months after the onset of symptoms. The researchers measured antibodies, memory…

Read More

Editor's Note The Centers for Disease Control and Prevention (CDC) on January 8 updated its guidance to clarify that overlapping may occur in phases of vaccinating priority groups, Reuters reports. The CDC reiterated that priority recipients of the COVID-19 vaccines are still healthcare workers, nursing home residents, those aged 75…

Read More

Editor's Note This decision analytical model from researchers at the Centers for Disease Control and Prevention finds that transmission of COVID-19 by asymptomatic individuals accounts for more than half of all transmissions. Combining baseline assumptions that peak infectiousness occurs at the median of symptom onset and that 30% never develop…

Read More

Editor's Note Cori L. Ofstead, MSPH, President and CEO of Ofstead & Associates, has announced that Ofstead & Associates is offering all of their webinars for free until January 21. The CE-eligible webinars include: Uncovering device adverse events to improve safety for patients and personnel Respiratory protection: Unmasked. A selection…

Read More